World ADC San Diego 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Biotech companies at World ADC San Diego 2026

Oct 12–15, 2026 San Diego, CA ~1.3k attendees Website

42 biotech companies are at World ADC San Diego 2026 — 78 presentations on the program. Most represented: Callio Therapeutics (4 on the program), Exelixis (4 on the program), Iksuda Therapeutics (3 on the program). 25 of them have their own page in this guide. As of Oct 8, 2026.

All 165 organizations at World ADC San Diego 2026 →

Showing 1–9 of 42 organizations

Organization	World ADC San Diego 2026 Attendance
Callio Therapeutics
calliotx.com Biotech Clinical-stage biotech developing dual-payload ADCs, led by a HER2-targeted program, to counter tumor resistance.	Talk Tue Oct 13 12:00pm From Complexity to Manufacturability: Considerations to Rapidly Develop & Manufacture Dual Payload ADCs Manufacturing & Supply Chain Talk Tue Oct 13 2:00pm Harnessing the Promise of Dual Payload ADCs to Combat Resistance to Traditional ADCs Discovery Chemistry Panel Tue Oct 13 3:30pm What’s the New Path to the Next Generation of ADCs? Discovery Biology · with Sygnature Discovery, AstraZeneca, Iksuda Therapeutics +1 more Panel Tue Oct 13 5:45pm Building the Next Generation of ADC Linkers & Payloads: What do Innovators Need from Development & Manufacturing Partners? Plenary · with Exelixis, Genentech, Veranova +1 more ADC discovery chemistryManufacturing & supply chain Chair Enhancing ADC Quality Characterization & Process Control to Rapidly & Confidently Produce Complex Conjugates Process & Analytical Development Talk Wed Oct 14 12:00pm Leveraging a Modular & Adaptable Linker Design to Evaluate Translation of Rationally Selected Dual Payload Combinations Preclinical
Exelixis Alameda, CA
exelixis.com Biotech Oncology company with marketed cabozantinib and a pipeline of biotherapeutics, including masked ADCs.	Chair Manufacturing Cost Efficient & Regulatory Compliant ADCs at Scale Pre-conference: 8th CMC Day Panel Mon Oct 12 10:30am Discussing Best Practices & Opportunities With Existing ADC Regulatory CMC Legislation & Data Submissions Pre-conference: 8th CMC Day Talk Mon Oct 12 10:30am Evaluating Design & Preclinical Characterization of XB404, a Masked ADC Targeting ROR1 & ROR2 Pre-conference: 3rd Pharmacology Day Talk Tue Oct 13 2:00pm Navigating Platform Process Development Approaches to Ensure mAb Readiness for Diverse Conjugation Approaches Process & Analytical Development Panel Tue Oct 13 5:45pm Building the Next Generation of ADC Linkers & Payloads: What do Innovators Need from Development & Manufacturing Partners? Plenary · with Genentech, Callio Therapeutics, Veranova +1 more ADC discovery chemistryManufacturing & supply chain Talk Wed Oct 14 12:00pm Exploring Design & Preclinical Characterization of XB773, a Novel Anti-DLL3 Targeting ADC Discovery Biology
Iksuda Therapeutics Newcastle upon Tyne, UK
iksuda.com Biotech UK ADC developer with clinical programs and new payload classes, including a protein-alkylating payload.	Chair Tue Oct 13 7:55am Part of Striving for the Next Wave of ADC Innovation: Contextualizing Novel ADC Mechanism & Design Validation to De-Risk Future ADC Development & Deliver Differentiated Patient Benefit Chair’s Opening Remarks Plenary ADC discovery chemistryADC discovery biology Panel Tue Oct 13 8:00am Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact Plenary · with Amgen, Daiichi Sankyo, Pfizer +1 more ADC discovery chemistryADC discovery biology Talk Tue Oct 13 2:00pm Beyond TopoI & Tubulin: Advancing a First-in-Class Protein Alkylation Payload ADC IKS073 Preclinical Talk Tue Oct 13 3:00pm Spotlighting the Clinical Profile & Positioning of IKS014 to Contextualize ADC Sequencing Clinical Lessons Panel Tue Oct 13 3:30pm What’s the New Path to the Next Generation of ADCs? Discovery Biology · with Sygnature Discovery, AstraZeneca, Pfizer +1 more Chair Navigating New & Crowded ADC Clinical Indications to Achieve Differentiation & Maximize Benefit to Patients Clinical Lessons Panel Wed Oct 14 12:30pm Navigating & Maximizing ADC Clinical Development to Best Deliver Patient Impact in Crowded Oncology Indications Clinical Lessons Panel Wed Oct 14 3:00pm Exploring Opportunities to Achieve Differentiated Clinical Benefit in a Crowded ADC Landscape Clinical Lessons Chair Wed Oct 14 5:30pm Part of Delving Into ADC Performance in Crowded Clinical Indications With Approved ADC Therapies to Understand How Differences in Biconjugate Design & Clinical Strategy Correlates to Patient Impact Chair’s Closing Remarks Plenary Clinical development Workshop Thu Oct 15 9:00am Connecting ADC Design & Component Contribution to Clinical Safety & Efficacy: What Makes a Clinically Impactful ADC? Post-conference workshop for Translational Medicine & Clinical Lessons
Sutro Biopharma South San Francisco, CA
sutrobio.com Biotech Develops ADCs using cell-free protein synthesis for site-specific conjugation, including STRO-004 and dual-payload candidates.	Talk Mon Oct 12 12:30pm Exploring Next-Generation High DAR TOPO1i x DDRi Dual Payload ADCs to Improve Efficacy, Overcome Resistance & Enhance Safety Pre-conference: 10th ADCs in Combination Day Chair Leveraging Novel Payload MoAs & Combinations to Differentiate ADC Mechanisms & Combat Patient Resistance Discovery Chemistry Talk Tue Oct 13 9:30am Unveiling the Early Clinical Safety & PK Profile of STRO-004 to Understand How Enhanced Design & Preclinical Characterization Links to Differentiated ADC Clinical Performance Plenary Clinical developmentPreclinical development Talk Tue Oct 13 12:00pm Driving Clinical Success With STRO-006: Breaking Down Insights From PDX Response & Translational Biomarkers Preclinical Panel Tue Oct 13 5:45pm Building the Next Generation of ADC Linkers & Payloads: What do Innovators Need from Development & Manufacturing Partners? Plenary · with Exelixis, Genentech, Callio Therapeutics +1 more ADC discovery chemistryManufacturing & supply chain Talk Wed Oct 14 2:30pm Breaking Down Preclinical Characterization of STRO-227 Dual Payload ADC to Evaluate Efficacy & Safety in ADC Resistance Models Preclinical
Aarvik Therapeutics Hayward, CA
aarviktx.com Biotech Develops antibody-drug conjugates on its MUTTA platform of tetravalent multifunctional antibodies aimed at low-expression tumor targets.	Talk Mon Oct 12 12:30pm Developing Hydrophilic ADCs via Engineering Novel Short Linkers & Antibody Conjugation Sites Pre-conference: 3rd Pharmacology Day Talk Tue Oct 13 11:00am MUTTA ADC Platform: Engineering Novel Dual Targeting ADCs With an Improved Therapeutic Window Discovery Biology
CanWell Pharma Woburn, MA
canwellpharma.com Biotech Develops dual- and multi-payload ADCs on its StarLinker platform, plus TLR7 immune-agonist programs for cancer.	Talk Wed Oct 14 11:00am Exploring the Preclinical Profile & IND Journey of Dual Payload ADC CAN016 for HER2 Refractory Patients Translational Medicine Talk Wed Oct 14 2:00pm Spotlighting Clinical Performance of CAN1012: A TLR7 Agonist for the Treatment of PD-1 Refractory Melanoma & Dedifferentiated Liposarcoma Clinical Lessons
OBI Pharma Taipei, Taiwan
obipharma.com Biotech Taiwanese oncology biotech developing ADCs, including bispecific and dual-payload designs, using enzymatic glycan-site conjugation.	Talk Mon Oct 12 2:00pm Best of Both Worlds? Spotlighting Discovery of Bispecific, Dual Payload ADC OBI-221: 2 + 2 = Innovation Pre-conference: 4th Novel Conjugates Day Talk Wed Oct 14 12:00pm Evaluating Enzymatic Conjugation Strategies to Improve Dual Payload ADC Therapeutic Index at the Discovery Stage Discovery Chemistry
Kivu Bioscience San Mateo, CA
kivubioscience.com Biotech Develops ADCs with topoisomerase I inhibitor payloads, led by the PTK7-targeted KIVU-107 in a Phase 1 trial.	Talk Tue Oct 13 11:00am Optimizing ADC Design, Preclinical Evaluation & Clinical Trial Design for Clinical Development Success Translational Medicine Chair Tue Oct 13 6:45pm Part of Demonstrating the Transformative Impact of ADCs to Reshape the Standard of Oncology Care & Deliver Improved Therapeutic Outcomes for Patients in Metastatic & Early-Stage Settings Chair’s Closing Remarks Plenary Clinical development Chair Wed Oct 14 7:55am Part of Beyond the Topo1 Dogma: Unveiling Rationale-Driven Novel Payload Development & Properties to Herald ADCs with New Mechanisms & Improved Therapeutic Index Chair’s Opening Remarks Plenary ADC discovery chemistry
NEOK Bio
neokbio.com Biotech Develops bispecific ADCs for solid tumors, including NEOK001 (B7-H3 x ROR1) and NEOK002 (EGFR x MUC1), both in Phase 1.	Chair Innovating Antibody Targeting & Engineering to Improve ADC Therapeutic Properties & Unlock New Treatment Indications Discovery Biology Talk Tue Oct 13 12:00pm The Emerging Wave of Bispecific ADCs: Breaking Down Design & Rationale for NEOK001 & NEOK002 Discovery Biology Workshop Thu Oct 15 1:00pm Breaking Down Clinical Characterization & Differentiation Strategies to Set Up ADC Development for Success in an Increasingly Busy Oncology Landscape Post-conference workshop for Translational Medicine & Clinical Lessons · with Daiichi Sankyo